154 related articles for article (PubMed ID: 22248134)
21. Neuropsychiatric effects of Parkinson's disease treatment.
Aarons S; Peisah C; Wijeratne C
Australas J Ageing; 2012 Sep; 31(3):198-202. PubMed ID: 22950594
[TBL] [Abstract][Full Text] [Related]
22. Nude photography: abuse, obsession, delusion, and finally depression.
Müller H; Knossalla F; Breuer L; Kornhuber J; Marquardt L
Am J Med; 2012 Aug; 125(8):e3. PubMed ID: 22608787
[No Abstract] [Full Text] [Related]
23. [Impulse control behaviors associated with antiparkinsonian medications].
Depierreux-Lahaye F; Crémers J; Skawiniak E; Parmentier E; Delvaux V; Garraux G
Rev Med Liege; 2013; 68(5-6):221-5. PubMed ID: 23888568
[TBL] [Abstract][Full Text] [Related]
24. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
25. Impulse control disorders and subthalamic nucleus stimulation in Parkinson's disease: are we jumping the gun?
Moro E
Eur J Neurol; 2009 Apr; 16(4):440-1. PubMed ID: 19348620
[No Abstract] [Full Text] [Related]
26. Levodopa addiction in non-parkinsonian patients.
Steiner I; Wirguin I
Neurology; 2003 Nov; 61(10):1451. PubMed ID: 14638980
[No Abstract] [Full Text] [Related]
27. [Diagnosis and therapy of Parkinson's disease].
Wittstock M; Benecke R
MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
[TBL] [Abstract][Full Text] [Related]
28. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
Wenzelburger R
Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
[No Abstract] [Full Text] [Related]
29. Dopaminergic drugs, paraphilic fantasies, paraphilic behaviours and creativity in Parkinson's disease.
Cannas A; Solla P; Floris GL; Serra C; Costantino E; Piras V; Marrosu F; Marrosu MG
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):563-4. PubMed ID: 20153398
[No Abstract] [Full Text] [Related]
30. Stimulating debate in the field of addiction.
Carter A; Hall W; Ambermoon P; Dissanayaka N; O'Sullivan J
Addiction; 2012 Feb; 107(2):253. PubMed ID: 22248135
[No Abstract] [Full Text] [Related]
31. [Parkinson's disease and obsessive-compulsive spectrum].
López-Moríñigo JD; Ramos-Ríos R; Martínez-Formoso S; Arrojo-Romero M; Ecénarro-Tomé P
Rev Neurol; 2009 Aug 16-31; 49(4):202-9. PubMed ID: 19621323
[TBL] [Abstract][Full Text] [Related]
32. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
Weintraub D; Koester J; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
Arch Neurol; 2010 May; 67(5):589-95. PubMed ID: 20457959
[TBL] [Abstract][Full Text] [Related]
33. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Lange KW; Paul GM; Naumann M; Gsell W
J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
[TBL] [Abstract][Full Text] [Related]
34. [Dopamine dysregulation syndrome in a patient with Parkinson's disease; a case report].
Hol WM; van der Zwaard R; Hovestadt A; van Megen HJ
Tijdschr Psychiatr; 2010; 52(4):259-63. PubMed ID: 20503167
[TBL] [Abstract][Full Text] [Related]
35. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
[No Abstract] [Full Text] [Related]
36. Medications for Parkinson's disease.
Whitney CM
Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
[No Abstract] [Full Text] [Related]
37. Rehabilitation goals and strategies in Parkinson's disease.
Ceravolo MG
Eur J Phys Rehabil Med; 2009 Jun; 45(2):205-8. PubMed ID: 19532108
[No Abstract] [Full Text] [Related]
38. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
39. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
Ahlskog JE
Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
[TBL] [Abstract][Full Text] [Related]
40. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
Weintraub D; Sohr M; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
Ann Neurol; 2010 Dec; 68(6):963-8. PubMed ID: 21154480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
